Effect of access to germline genetic testing on pancreatic cancer precision treatment across disease stage and ethnicity.

Edward D. Esplin,Rebecca Truty,Shan Yang,Sarah M. Nielsen,Margaret Klint,Stephen E. Lincoln,Nhu Ngo,Kingshuk Das,Jewel Samadder,Robert L. Nussbaum

Effect of access to germline genetic testing on pancreatic cancer precision treatment across disease stage and ethnicity.

2020

Edward D. Esplin
Rebecca Truty
Shan Yang
Sarah M. Nielsen
Margaret Klint
Stephen E. Lincoln
Nhu Ngo
Kingshuk Das
Jewel Samadder
Robert L. Nussbaum

e16783Background: PARP inhibitor (PARPi) treatment was recently approved for pancreatic cancer (PaCa) patients with germline mutations in 2 DNA damage repair (DDR) genes. Despite criteria recommend...

Keywords:

Oncology
Ethnic group
Genetic testing
Internal medicine
Pancreatic cancer
Germline
Pathology
Disease
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations